Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Gotham Asset Management LLC

Gotham Asset Management LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 211.9% in the 3rd quarter, Holdings Channel reports. The firm owned 84,230 shares of the biopharmaceutical company’s stock after purchasing an additional 57,225 shares during the period. Gotham Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $47,360,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in REGN. Brighton Jones LLC boosted its stake in Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after purchasing an additional 686 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at about $226,000. Allworth Financial LP raised its position in shares of Regeneron Pharmaceuticals by 21.1% in the second quarter. Allworth Financial LP now owns 994 shares of the biopharmaceutical company’s stock valued at $522,000 after buying an additional 173 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in shares of Regeneron Pharmaceuticals by 5.9% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 25,469 shares of the biopharmaceutical company’s stock worth $13,371,000 after buying an additional 1,409 shares in the last quarter. Finally, Westwood Holdings Group Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 17.0% in the second quarter. Westwood Holdings Group Inc. now owns 13,556 shares of the biopharmaceutical company’s stock worth $7,117,000 after buying an additional 1,974 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Evercore upped their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a research note on Thursday, January 22nd. Wells Fargo & Company raised their target price on shares of Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an “equal weight” rating in a research note on Monday, February 2nd. Bank of America upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and boosted their target price for the stock from $627.00 to $860.00 in a report on Wednesday, January 7th. Truist Financial dropped their price target on Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Finally, Morgan Stanley increased their price target on Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a report on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $802.27.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $745.77 on Monday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11. The stock’s fifty day moving average is $769.73 and its two-hundred day moving average is $695.68. The company has a market capitalization of $78.84 billion, a P/E ratio of 17.94, a P/E/G ratio of 2.00 and a beta of 0.40. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The business had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company’s revenue was up 2.5% compared to the same quarter last year. During the same period in the prior year, the business posted $12.07 EPS. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were given a $0.94 dividend. The ex-dividend date of this dividend was Friday, February 20th. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.05%.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 1,638 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.53, for a total transaction of $77,853.00. Following the completion of the sale, the director directly owned 17,803 shares in the company, valued at $13,860,169.59. This trade represents a 0.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 5,274 shares of company stock worth $4,142,738. 7.02% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.